Literature DB >> 16311757

Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.

Lisa Mosconi1, Susan De Santi, Yi Li, Juan Li, Jiong Zhan, Wai Hon Tsui, Madhu Boppana, Alberto Pupi, Mony J de Leon.   

Abstract

PURPOSE: This study was designed to examine the utility of visual inspection of medial temporal lobe (MTL) metabolism in the diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) using FDG-PET scans.
METHODS: Seventy-five subjects [27 normal controls (NL), 26 MCI, and 22 AD] with FDG-PET and MRI scans were included in this study. We developed a four-point visual rating scale to evaluate the presence and severity of MTL hypometabolism on FDG-PET scans. The visual MTL ratings were compared with quantitative glucose metabolic rate (MR(glc)) data extracted using regions of interest (ROIs) from the MRI-coregistered PET scans of all subjects. A standard rating evaluation of neocortical hypometabolism was also completed. Logistic regressions were used to determine and compare the diagnostic accuracy of the MTL and cortical ratings.
RESULTS: For both MTL and cortical ratings, high intra- and inter-rater reliabilities were found (p values <0.001). The MTL rating was highly correlated with and yielded a diagnostic accuracy equivalent to the ROI MR(glc) measures (p values <0.001). The combination of MTL and cortical ratings significantly improved the diagnostic accuracy over the cortical rating alone, with 100% of AD, 77% of MCI, and 85% of NL cases being correctly identified.
CONCLUSION: This study shows that the visual rating of MTL hypometabolism on PET is reliable, yields a diagnostic accuracy equal to the quantitative ROI measures, and is clinically useful and more sensitive than cortical ratings for patients with MCI. We suggest this method be further evaluated for its potential in the early diagnosis of AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311757     DOI: 10.1007/s00259-005-1956-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  51 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

3.  Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease.

Authors:  A Convit; M J De Leon; C Tarshish; S De Santi; W Tsui; H Rusinek; A George
Journal:  Neurobiol Aging       Date:  1997 Mar-Apr       Impact factor: 4.673

4.  Use of methodological standards in diagnostic test research. Getting better but still not good.

Authors:  M C Reid; M S Lachs; A R Feinstein
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

5.  The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation.

Authors:  M J de Leon; J Golomb; A E George; A Convit; C Y Tarshish; T McRae; S De Santi; G Smith; S H Ferris; M Noz
Journal:  AJNR Am J Neuroradiol       Date:  1993 Jul-Aug       Impact factor: 3.825

6.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

7.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

8.  Altered glucose metabolism in the hippocampal head in memory impairment.

Authors:  Y Ouchi; S Nobezawa; H Okada; E Yoshikawa; M Futatsubashi; M Kaneko
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

9.  Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.

Authors:  S Minoshima; K A Frey; N L Foster; D E Kuhl
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

10.  MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

Authors:  L Mosconi; D Perani; S Sorbi; K Herholz; B Nacmias; V Holthoff; E Salmon; J-C Baron; M T R De Cristofaro; A Padovani; B Borroni; M Franceschi; L Bracco; A Pupi
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

View more
  25 in total

Review 1.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

2.  Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease.

Authors:  Lisa Mosconi; Wai H Tsui; Henry Rusinek; Susan De Santi; Yi Li; Gene-Jack Wang; Alberto Pupi; Joanna Fowler; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-04       Impact factor: 9.236

3.  Hippocampal hypometabolism predicts cognitive decline from normal aging.

Authors:  Lisa Mosconi; Susan De Santi; Juan Li; Wai Hon Tsui; Yi Li; Madhu Boppana; Eugene Laska; Henry Rusinek; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-01-11       Impact factor: 4.673

Review 4.  Positron emission tomography scans obtained for the evaluation of cognitive dysfunction.

Authors:  Daniel H S Silverman; Lisa Mosconi; Linda Ercoli; Wei Chen; Gary W Small
Journal:  Semin Nucl Med       Date:  2008-07       Impact factor: 4.446

Review 5.  [Diagnosis without therapy: early diagnosis of Alzheimer's disease in the stage of mild cognitive impairment].

Authors:  H-J Gertz; A Kurz
Journal:  Nervenarzt       Date:  2011-09       Impact factor: 1.214

Review 6.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 7.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 8.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

9.  Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.

Authors:  Lisa Mosconi; Wai H Tsui; Karl Herholz; Alberto Pupi; Alexander Drzezga; Giovanni Lucignani; Eric M Reiman; Vjera Holthoff; Elke Kalbe; Sandro Sorbi; Janine Diehl-Schmid; Robert Perneczky; Francesca Clerici; Richard Caselli; Bettina Beuthien-Baumann; Alexander Kurz; Satoshi Minoshima; Mony J de Leon
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

10.  Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.

Authors:  Rachel Mistur; Lisa Mosconi; Susan De Santi; Marla Guzman; Yi Li; Wai Tsui; Mony J de Leon
Journal:  J Clin Neurol       Date:  2009-12-31       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.